ReCode Combines With TranscripTx, Raises $80m For Novel RNA Drugs
Executive Summary
ReCode, whose platform allows for organ-specific delivery of RNA therapies, plans to start clinical trials in 2022 for its two lead programs in primary ciliary dyskinesia and cystic fibrosis.
You may also be interested in...
ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.
Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
The Next Big Thing In Gene Therapy Might Not Be Gene Therapy
Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.